Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Fuji
Chinese Patent Office
QuintilesIMS
Accenture
Cantor Fitzgerald
Federal Trade Commission
Merck
Queensland Health

Generated: May 26, 2018

DrugPatentWatch Database Preview

Vicuron Company Profile

« Back to Dashboard

Summary for Vicuron
International Patents:64
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Vicuron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes 5,965,525 ➤ Sign Up Y Y ➤ Sign Up
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes 6,960,564 ➤ Sign Up Y ➤ Sign Up
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 RX Yes Yes 5,965,525 ➤ Sign Up Y Y ➤ Sign Up
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes 7,709,444 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Vicuron

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 6,384,013 ➤ Sign Up
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 6,384,013 ➤ Sign Up
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 6,743,777 ➤ Sign Up
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 6,743,777 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Vicuron

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,743,777 Cyclic peptide antifungal agents and process for preparation thereof ➤ Sign Up
5,932,543 Cyclic peptide antifungal agents and process for preparation thereof ➤ Sign Up
7,790,744 Cyclic peptide antifungal agents and process for preparation thereof ➤ Sign Up
6,916,784 Cyclic peptide antifungal agents and process for preparation thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Vicuron Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C002/2008 Ireland ➤ Sign Up SPC002/2008: 20081105, EXPIRES: 20180317
C0009 France ➤ Sign Up PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
406 Luxembourg ➤ Sign Up 91406, EXPIRES: 20180318
C/GB08/016 United Kingdom ➤ Sign Up PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Baxter
Deloitte
UBS
Teva
Queensland Health
Chinese Patent Office
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.